Our data suggest that high STMN1 expression may serve as a clinical indicator of poor response to these treatments and that targeted strategies to inhibit STMN1 could potentially improve therapeutic outcomes for patients with advanced PCa. This evidence concerns the gene STMN1 and posterior cortical atrophy.